刘建出任广药集团战略科学家

新京报07-07

新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。　　加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。刘建曾在辉瑞、赛诺菲、阿斯利康、诺华、强生制药多家外资医药企业从事新药开发、投融资管理和药物流通工作多年。　　此次出任...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2649714608?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-07 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649714608","market":"hk","top_or_hot":-1,"title":"刘建出任广药集团战略科学家","media":"新京报","content":"<div>\n<p>新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。　　加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。刘建曾在辉瑞、赛诺菲、阿斯利康、诺华、强生制药多家外资医药企业从事新药开发、投融资管理和药物流通工作多年。　　此次出任...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607073796142441.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>刘建出任广药集团战略科学家</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n刘建出任广药集团战略科学家\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-07 09:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202607073796142441.html><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。　　加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。刘建曾在辉瑞、赛诺菲、阿斯利康、诺华、强生制药多家外资医药企业从事新药开发、投融资管理和药物流通工作多年。　　此次出任...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607073796142441.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607073796142441.html","article_id":"2649714608","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607073796142441.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649714608","pubTimestamp":1783388760,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","06160":"百济神州","BK1500":"做空集合股","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1588":"回港中概股","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD"},"translate_title":"Liu Jian appointed as strategic scientist of GPHL","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":0.6,"06160":0.9},"content_text":"新京报讯从百济神州离任后，刘建找到了新东家。7月6日，广药集团宣布，刘建加盟广药集团，出任广药集团战略科学家。　　加入广药集团前，刘建任百济神州全球执委会委员、创新中心首席执行官及生物药业董事长。在任期间，刘建领导了百济神州创新中心的创新药物孵化业务及百济神州广州生物药生产基地。刘建曾在辉瑞、赛诺菲、阿斯利康、诺华、强生制药多家外资医药企业从事新药开发、投融资管理和药物流通工作多年。　　此次出任广药集团战略科学家，刘建将成为广药集团创新转型战略发展的核心成员。（文章来源：新京报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649714608","isCrawlerRequest":true}